7 April 2016 - Novartis announced today that the European Commission (EC) has approved Revolade (eltrombopag olamine) for the treatment of pediatric (aged 1 year and above) chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

The approval includes the use of tablets as well as a new oral suspension formulation of Revolade, which is designed for younger children who may not be able to swallow tablets. Revolade was approved by the EC in 2010 for use in adults with the same condition.

For more details, go to: https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-revolader-first-class-therapy-children-aged-1-year